DuPont sets post-spin-off minimum EBITDA at $1.4 billion after Qnity separation

DuPont completed the Qnity Electronics spin-off and allocated applicable percentages of 56% to DuPont and 44% to Qnity under the Separation and Distribution Agreement, establishing a minimum EBITDA requirement for DuPont of $1.4 billion per prior agreements. In Q3 2025 DuPont reported adjusted EPS of $1.09 versus $1.16 expected (−6.03% surprise) and revenue of $3.10B versus $3.31B expected (−6.34%); Moody’s moved the outlook to stable from negative, a 2048-note tender offer was oversubscribed with $936.618M tendered (vs. $739.256M sought), and analysts revised targets (RBC to $48 from $100, KeyBanc to $45 from $44).

Analysis

Market structure: The Qnity spin and DuPont’s 56% applicable share plus a $1.4bn minimum EBITDA floor materially de-risks bondholders and creates a clearer free‑cash‑flow pivot for equity. Equity investors face near-term headwinds from a Q3 revenue/EPS miss (-6% each) and a large analyst reset (RBC PT cut to $48 from $100), but Moody’s move to stable and an oversubscribed tender ($936.6m vs $739.3m sought) signal improving credit dynamics that should tighten credit spreads and support long‑dated debt performance over 3–12 months.

Risk assessment: Tail risks include an LTM EBITDA breach triggering covenant remedies or restricted buybacks (probability medium, impact high) and a downturn in industrial demand that compresses margins across specialty materials. Immediate risk (days) is continued analyst volatility and options skew; short term (weeks–months) is confirmation of post‑spin cost run‑rate and tender finalization; long term (quarters–years) is whether DuPont can deliver the 8–10% EPS growth cited by RBC without aggressive buybacks. Hidden dependencies: successful cash conversion and working capital normalization are required to translate leverage improvement into shareholder returns.

Trade implications: Direct plays: selective long exposure to DD if price dislocates below key technical/valuation levels (see decisions). Credit trade: overweight DuPont senior debt vs high‑yield chemical peers given deleveraging; expect spread compression 50–150bp if Moody’s remains stable. Options: favor buying 9–12 month call LEAPs as convexity play around proof of EBITDA >$1.4bn and coupon reduction; sell near‑term implied vol via covered calls to harvest premium until catalysts resolve.

Contrarian angles: Consensus focuses on the miss and PT cuts but underweights the structural credit improvement and excess tender participation which reduce refinancing risk — this could be underpriced in equity. The market may be overreacting to one quarter’s top‑line weakness; if DuPont hits LTM EBITDA ≥ $1.4bn in the next two quarters and demonstrates >$500m of net debt reduction, upside to consensus PTs (mid‑$40s) is plausible. Conversely, don’t ignore the possibility that operational cyclicality could push EBITDA under covenant levels in a recession scenario.

Key Decisions for Investors

• If DD < $40, establish a 2–3% long position with a 6–12 month horizon targeting $45–$50; immediately hedge by buying 6‑month 10% OTM puts (size = 50–75% of equity notional) to cap downside while keeping upside exposure.
• If DD trades above $45, sell 30–60 day covered calls (strike +5–10% OTM) to generate yield until an EBITDA print confirms LTM ≥ $1.4bn; unwind on a confirmed miss or if implied vol spikes >30% above 90‑day average.
• Implement a credit overweight: buy DuPont senior bonds in the 5–8yr bucket if spread to swaps >200bp (expect 50–150bp compression if leverage improvement holds); size 3–5% portfolio notional and use 1–2yr rolling duration risk management.
• Pair trade: long DD equity (2%) vs short LyondellBasell (LYB) 1:1 for 6–12 months to isolate idiosyncratic deleveraging upside; trim if DuPont LTM EBITDA falls below $1.4bn or if LYB outperforms by >8% relative.